NICE endorses use of sofosbuvir-velpatasvir in chronic hepatitis C

Sofosbuvir-velpatasvir has been recommended by NICE as an option for treating chronic hepatitis C in adults, with specific recommendations made according to patients' HCV genotype, liver disease stage and treatment history.

NICE recommends that the decision to treat and prescribing decisions are made by multidisciplinary teams in the operational delivery networks put in place by NHS England, to prioritise treatment for people with the highest unmet clinical need.

The combination therapy, available in the UK as Epclusa, must be provided by the company in accordance with the simple discount agreement. Patients already being treated with the drug may continue without change according to whatever funding arrangements were in place before the guidance was issued until they and their NHS clinician consider it appropriate to stop.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New products - live tracker

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...

Drug price changes - live tracker

Drug price changes - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

Direct-acting oral anticoagulants set for wider use under NHS deal

Direct-acting oral anticoagulants set for wider use under NHS deal

More than half a million more people will be able to...

NICE recommends SGLT2 inhibitors for chronic kidney disease

NICE recommends SGLT2 inhibitors for chronic kidney disease

Updated NICE guidance on type II diabetes recommends...